International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

dc.contributor.author	Dombret, H.
dc.contributor.author	Seymour, John F.
dc.contributor.author	Butrym, Aleksandra
dc.contributor.author	Bernal del Castillo, Teresa
dc.date.accessioned	2015-12-21T10:40:10Z
dc.date.available	2015-12-21T10:40:10Z
dc.date.issued	2015
dc.identifier.citation	Blood, 126(3), p. 291-299 (2015); doi:10.1182/blood-2015-01-621664
dc.identifier.issn	0006-4971
dc.identifier.uri	http://hdl.handle.net/10651/34256
dc.description.statementofresponsibility	Dombret, H., Seymour, J.F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J.H., Kumar, R., Cavenagh, J., Schuh, A.C., Candoni, A., Récher, C., Sandhu, I., Del Castillo, T.B., Al-Ali, H.K., Martinelli, G., Falantes, J., Noppeney, R., Stone, R.M., Minden, M.D., McIntyre, H., Songer, S., Lucy, L.M., Beach, C.L., Döhner, H.
dc.format.extent	p. 291-299
dc.language.iso	eng
dc.relation.ispartof	Blood
dc.rights	© 2015 by The American Society of Hematology
dc.source	Scopus
dc.source.uri	http://www.scopus.com/inward/record.url?eid=2-s2.0-84937804118&partnerID=40&md5=d92ac90789ba9db73a95dd48ca4a8bac
dc.title	International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
dc.type	journal article
dc.identifier.doi	10.1182/blood-2015-01-621664
dc.relation.publisherversion	http://dx.doi.org/10.1182/blood-2015-01-621664

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.